BioNTech
Develops personalized immunotherapies with a focus on cancer medicine.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $145m | Grant | |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 3834 % | (9 %) | (78 %) | (28 %) | (19 %) | 1 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 79 % | 76 % | 30 % | 5 % | (61 %) | (66 %) | (65 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 54 % | 55 % | 24 % | (24 %) | (43 %) | (43 %) | (38 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 47 % | 82 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
BioNTech is a biotechnology company focused on developing and commercializing innovative immunotherapies for the treatment of cancer and infectious diseases. Founded by scientists and physicians, BioNTech operates in the biopharmaceutical market, serving patients worldwide. The company leverages its expertise in mRNA technology to create personalized vaccines and therapies that stimulate the immune system to fight diseases. BioNTech collaborates with global partners to advance its diversified clinical pipeline, which includes treatments for various cancers and infectious diseases with high unmet medical needs. The company generates revenue through the development and commercialization of its therapies, as well as through partnerships and potential royalty payments from its lead cell therapy candidates. BioNTech is committed to equitable access to its innovative medicines, aiming to address pressing global health challenges.
Keywords: mRNA technology, immunotherapies, cancer treatment, infectious diseases, personalized vaccines, biopharmaceutical, clinical pipeline, global partnerships, innovative medicines, equitable access.
Tech stack
Investments by BioNTech
Edit
